Long-term Outcomes of Group B Streptococcal Meningitis

Vanderbilt Vaccine Research Program, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
PEDIATRICS (Impact Factor: 5.47). 06/2012; 130(1):e8-15. DOI: 10.1542/peds.2011-3453
Source: PubMed


Group B Streptococcus (GBS) is the leading cause of meningitis in young infants. We evaluated long-term outcomes among GBS meningitis survivors. We hypothesized that despite reduced mortality, GBS meningitis would remain a significant cause of morbidity among GBS survivors.
Ninety term and near-term infants diagnosed with GBS meningitis from 1998 through 2006 were identified from 2 children's hospitals. Five died acutely, and 5 died at 6 months to 3 years of age. Forty-three survivors (54%; mean age 6.8, range 3-12 years) were consented for evaluation and underwent physical and neurologic examinations, hearing and vision screening, and standardized developmental assessments. Associations among presenting features, laboratory parameters, neurologic status at hospital discharge, and later developmental outcomes were explored by using descriptive statistics and logistic regression.
Twenty-four of 43 (56%) children evaluated demonstrated age-appropriate development, 11 (25%) had mild-to-moderate impairment, and 8 (19%) had severe impairment. Admission features associated with death after hospital discharge or severe impairment included lethargy (P = .003), respiratory distress (P = .022), coma or semicoma (P = .022), seizures (P = .015), bulging fontanel (P = .034), leukopenia (P = .026), acidosis (P = .024), cerebrospinal fluid protein >300 mg/dL (P = .006), cerebrospinal fluid glucose <20 mg/dL (P = .026), and need for ventilator (P = .002) or pressor support (P < .001). Features at discharge associated with late death or severe impairment included failed hearing screen (P = .004), abnormal neurologic examination (P < .001), and abnormal end of therapy brain imaging (P = .038).
Survivors of GBS meningitis continue to have substantial long-term morbidity, highlighting the need for ongoing developmental follow-up and prevention strategies such as maternal immunization.

Download full-text


Available from: Fatma Levent, Oct 22, 2015
  • Source
    • "The neurological sequelae consisted of severe (31.3% of all neurological sequellae), moderate (33.4%) and mild (35.3%) neurological disorders [18,19]. In addition a further 4.6% of meningitis cases suffered from severe or profound bilateral hearing loss [13]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In Israel, an average of 37 children are born each year with sepsis and another four with meningitis as a result of Group B Streptococcal (GBS) disease. Israel currently only screens mothers with defined risk factors (around 15% of all pregnancies) in order to identify candidates for Intrapartum Antiobiotic Prophyhlaxis (IAP) of GBS. This paper presents a cost-utility analysis of implementing an alternative strategy, which would expand the current protocol to one aiming to screen all pregnant women at 35-37 weeks gestation based on taking a vaginal culture for GBS. A spreadsheet model was built incorporating technical, epidemiological, health service costs, demographic and economic data based primarily on Israeli sources. The intervention of universal screening (compared with the current scenario) would increase screening costs from 580,000 NIS to 3,278,000 million NIS. In addition, the intervention would also increase penicillin costs from 39,000 NIS to 221,000 NIS. Current culture screening of approximately 15% of mothers-to-be with high risk factors resulted in 42 GBS births in 2008-9 (0.253/1000 births). Expanding culture screening to 85% of mothers-to-be, will decrease the number of GBS births to 17.3 (0.104/1000 births). The initial 2.9 million NIS incremental intervention costs are offset by decreased treatment costs of 1.9 million NIS and work productivity gains of 811,000 NIS as a result of a decrease in neurological sequelae from GBS caused meningitis. Thus the resultant net cost of the intervention is only around 134,000 NIS. Culture based screening will reduce the burden of disease by 12.6 discounted Quality Adjusted Life Years (QALYS), giving a very cost effective baseline incremental cost per QALY (cf. risk factor screening) of 10,641 NIS per QALY. The data was very sensitive to rates of anaphylactic shock and changes in the percentage of meningitis cases that had associated long term-sequelae. It is recommended that Israel adopt universal culture-based GBS screening.
    Israel Journal of Health Policy Research 02/2013; 2(1):6. DOI:10.1186/2045-4015-2-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a group B streptococcal (GBS) glycoconjugate vaccine and its upcoming evaluation in a phase 3 trial in pregnant women highlight the importance of defining the anticipated impact of GBS vaccination upon the broad spectrum of GBS-related perinatal morbidity and mortality. We present the specific pregnancy-associated and neonatal conditions attributable, at least in part, to GBS in high and lower income countries. We offer a rationale to support our contention that implementation of GBS glycoconjugate immunization during pregnancy will reduce the global burden of GBS-related morbidity and mortality in pregnant women and their infants.
    Vaccine 11/2012; 31. DOI:10.1016/j.vaccine.2012.11.046 · 3.62 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: To clarify the incidence and prognosis of early-onset (EOD) and late-onset (LOD) GBS disease in Japan. To evaluate the influence of national guidelines issued in 2008 on the epidemiology of GBS disease. METHODS: Retrospective nationwide questionnaire surveillance on culture-confirmed GBS infections between 2004 and 2010. RESULTS: Eighty-eight EOD and 162 LOD cases were reported from 152 participating hospitals. The case fatality of EOD was 13.6% and of LOD was 8.0%. Premature birth <37 weeks (p<0.001) and low birth weight <2500g (p<0.001) were significantly associated with EOD mortality. A high rate of neurological sequelae was noted in meningitis in EOD (8/24) and LOD (29/85) cases. Based on a live-birth number of 438 359 and inborn case numbers of 36 EOD and 42 LOD, the incidence of EOD and LOD were estimated to be 0.08 (95% confidence interval (CI) 0.06-0.11)/1000 and 0.10 (95% CI 0.07-0.12)/1000 live-births, respectively. Before (2004-2008) and after (2009-2010) the issue of guidelines, the mortality of EOD (from 14.8% to 11.8%) and LOD (from 9.8% to 2.5%) improved, but the incidence was unchanged. CONCLUSIONS: The incidence of EOD and LOD is apparently low in Japan, but the mortality and morbidity rates remain substantial. The issue of national guidelines did not affect the incidence.
    International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 01/2013; 17(6). DOI:10.1016/j.ijid.2012.11.027 · 1.86 Impact Factor
Show more